ProfileGDS4814 / ILMN_2147920
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 88% 88% 87% 86% 87% 87% 88% 87% 87% 87% 88% 86% 88% 87% 87% 87% 86% 88% 86% 87% 88% 88% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)304.09288
GSM780708Untreated after 4 days (C2_1)315.22188
GSM780709Untreated after 4 days (C3_1)288.18587
GSM780719Untreated after 4 days (C1_2)270.71286
GSM780720Untreated after 4 days (C2_2)282.10387
GSM780721Untreated after 4 days (C3_2)294.50887
GSM780710Trastuzumab treated after 4 days (T1_1)320.67188
GSM780711Trastuzumab treated after 4 days (T2_1)295.44687
GSM780712Trastuzumab treated after 4 days (T3_1)286.43887
GSM780722Trastuzumab treated after 4 days (T1_2)281.8787
GSM780723Trastuzumab treated after 4 days (T2_2)306.39788
GSM780724Trastuzumab treated after 4 days (T3_2)264.5686
GSM780713Pertuzumab treated after 4 days (P1_1)315.52988
GSM780714Pertuzumab treated after 4 days (P2_1)280.80587
GSM780715Pertuzumab treated after 4 days (P3_1)281.02487
GSM780725Pertuzumab treated after 4 days (P1_2)282.73187
GSM780726Pertuzumab treated after 4 days (P2_2)269.9586
GSM780727Pertuzumab treated after 4 days (P3_2)305.35388
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)259.92886
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)289.67787
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)307.04288
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)304.14888
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)287.78187